Impaired PGC-1α function in muscle in Huntington's disease

Human Molecular Genetics

Volumn 18, Issue 16, 2009, Pages 3048-3065

  Chaturvedi, Rajnish K ^a,d   Adhihetty, Peter ^a   Shukla, Shubha ^a   Hennessy, Thomas ^a   Calingasan, Noel ^a   Yang, Lichuan ^a   Starkov, Anatoly ^a   Kiaei, Mahmoud ^a   Cannella, Milena ^b   Sassone, Jenny ^c   Ciammola, Andrea ^c   Squitieri, Fernando ^b   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b IRCCS NEUROMED   (Italy)

^c Centro Dino Ferrari   (Italy)

^d CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOVIRUS VECTOR; GUANIDINOPROPIONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; TRANSCRIPTION FACTOR NRF1; HEAT SHOCK PROTEIN; PPARGC1A PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOGENESIS; CALORIC INTAKE; CATABOLISM; CONTROLLED STUDY; ELECTRON TRANSPORT; FEMALE; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE INTERACTION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; MITOCHONDRIAL RESPIRATION; MOTOR PERFORMANCE; MOUSE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE DISEASE; MYOBLAST; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PATHOGENESIS; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; WILD TYPE; ANIMAL; CELL CULTURE; DISEASE MODEL; GENETICS; METABOLISM; SKELETAL MUSCLE;

MUS; MUS MUSCULUS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HEAT-SHOCK PROTEINS; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; MYOBLASTS; TRANSCRIPTION FACTORS;

EID: 67650061723     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp243     Document Type: Article

References (76)

1. Pratley, R.E., Salbe, A.D., Ravussin, E. and Caviness, J.N. (2000) Higher sedentary energy expenditure in patients with Huntington's disease. Ann. Neurol., 47, 64-70.
2. Goodman, A.O., Murgatroyd, P.R., Medina-Gomez, G., Wood, N.I., Finer, N., Vidal-Puig, A.J., Morton, A.J. and Barker, R.A. (2008) The metabolic profile of early Huntington's disease - a combined human and transgenic mouse study. Exp. Neurol., 210, 691-698.
3. Djousse, L., Knowlton, B., Cupples, L.A., Marder, K., Shoulson, I. and Myers, R.H. (2002) Weight loss in early stage of Huntington's disease. Neurology, 59, 1325-1330.
4. Sathasivam, K., Hobbs, C., Turmaine, M., Mangiarini, L., Mahal, A., Bertaux, F., Wanker, E.E., Doherty, P., Davies, S.W. and Bates, G.P. (1999) Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet., 8, 813-822.
5. Ribchester, R.R., Thomson, D., Wood, N.I., Hinks, T., Gillingwater, T.H., Wishart, T.M., Court, F.A. and Morton, A.J. (2004) Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci., 20, 3092-3114.
6. Grafton, S.T., Mazziotta, J.C., Pahl, J.J., St George-Hyslop, P., Haines, J.L., Gusella, J., Hoffman, J.M., Baxter, L.R. and Phelps, M.E. (1992) Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch. Neurol., 49, 1161-1167.
7. Feigin, A., Leenders, K.L., Moeller, J.R., Missimer, J., Kuenig, G., Spetsieris, P., Antonini, A. and Eidelberg, D. (2001) Metabolic network abnormalities in early Huntington's disease: An [(18)F]FDG PET study. J. Nucl. Med., 42, 1591-1595.
8. Antonini, A., Leenders, K.L., Spiegel, R., Meier, D., Vontobel, P., Weigell-Weber, M., Sanchez-Pernaute, R., de Yebenez, J.G., Boesiger, P., Weindl, A. et al. (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain, 119 (Pt 6), 2085-2095.
9. Kuwert, T., Lange, H.W., Boecker, H., Titz, H., Herzog, H., Aulich, A., Wang, B.C., Nayak, U. and Feinendegen, L.E. (1993) Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. J. Neurol., 241, 31-36.
10. Jenkins, B.G., Koroshetz, W.J., Beal, M.F. and Rosen, B.R. (1993) Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology, 43, 2689-2695.
11. Koroshetz, W.J., Jenkins, B.G., Rosen, B.R. and Beal, M.F. (1997) Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol., 41, 160-165.
12. Lodi, R., Schapira, A.H., Manners, D., Styles, P., Wood, N.W., Taylor, D.J. and Warner, T.T. (2000) Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol., 48, 72-76.
13. Saft, C., Zange, J., Andrich, J., Muller, K., Lindenberg, K., Landwehrmeyer, B., Vorgerd, M., Kraus, P.H., Przuntek, H. and Schols, L. (2005) Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov. Disord., 20, 674-679.
14. Browne, S.E., Bowling, A.C., MacGarvey, U., Baik, M.J., Berger, S.C., Muqit, M.M., Bird, E.D. and Beal, M.F. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia. Ann. Neurol., 41, 646-653.
15. Gu, M., Gash, M.T., Mann, V.M., Javoy-Agid, F., Cooper, J.M. and Schapira, A.H. (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol., 39, 385-389.
16. Tabrizi, S.J., Cleeter, M.W., Xuereb, J., Taanman, J.W., Cooper, J.M. and Schapira, A.H. (1999) Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol., 45, 25-32.
17. Seong, I.S., Ivanova, E., Lee, J.M., Choo, Y.S., Fossale, E., Anderson, M., Gusella, J.F., Laramie, J.M., Myers, R.H., Lesort, M. et al. (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet., 14, 2871-2880.
18. Milakovic, T. and Johnson, G.V. (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J. Biol. Chem., 280, 30773-30782.
19. Beal, M.F., Brouillet, E., Jenkins, B., Henshaw, R., Rosen, B. and Hyman, B.T. (1993) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem., 61, 1147-1150.
20. Brouillet, E., Hantraye, P., Ferrante, R.J., Dolan, R., Leroy-Willig, A., Kowall, N.W. and Beal, M.F. (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl Acad. Sci. USA, 92 7105-7109.
21. Ludolph, A.C., He, F., Spencer, P.S., Hammerstad, J. and Sabri, M. (1991) 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci., 18, 492-498.
22. Brouillet, E., Jenkins, B.G., Hyman, B.T., Ferrante, R.J., Kowall, N.W., Srivastava, R., Roy, D.S., Rosen, B.R. and Beal, M.F. (1993) Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem., 60, 356-359.
23. Orr, A.L., Li, S., Wang, C.E., Li, H., Wang, J., Rong, J., Xu, X., Mastroberardino, P.G., Greenamyre, J.T. and Li, X.J. (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci., 28, 2783-271492.
24. Choo, Y.S., Johnson, G.V., MacDonald, M., Detloff, P.J. and Lesort, M. (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet., 13, 1407-1420.
25. Orth, M., Cooper, J.M., Bates, G.P. and Schapira, A.H. (2003) Inclusion formation in Huntington's disease R6/2 mouse muscle cultures. J. Neurochem., 87, 1-6.
26. Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J. and Greenamyre, J.T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 5, 731-736.
27. Cha, J.H. (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci., 23, 387-392.
28. Sugars, K.L. and Rubinsztein, D.C. (2003) Transcriptional abnormalities in Huntington disease. Trends Genet., 19, 233-238.
29. Chen-Plotkin, A.S., Sadri-Vakili, G., Yohrling, G.J., Braveman, M.W., Benn, C.L., Glajch, K.E., DiRocco, D.P., Farrell, L.A., Krainc, D., Gines, S. et al. (2006) Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. Neurobiol. Dis., 22, 233-241.
30. Dunah, A.W., Jeong, H., Griffin, A., Kim, Y.M., Standaert, D.G., Hersch, S.M., Mouradian, M.M., Young, A.B., Tanese, N. and Krainc, D. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science, 296, 2238-2243.
31. Nucifora, F.C. Jr, Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L. et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science, 291, 2423-2428.
32. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E. and Thompson, L.M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 97, 6763-6768.
33. Leone, T.C., Lehman, J.J., Finck, B.N., Schaeffer, P.J., Wende, A.R., Boudina, S., Courtois, M., Wozniak, D.F., Sambandam, N., Bernal-Mizrachi, C. et al. (2005) PGC-1alpha deficiency causes multi-system energy metabolic derangements: Muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol., 3, e101.
34. Lin, J., Wu, P.H., Tarr, P.T., Lindenberg, K.S., St-Pierre, J., Zhang, C.Y., Mootha, V.K., Jager, S., Vianna, C.R., Reznick, R.M. et al. (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell, 119, 121-135.
35. Puigserver, P. and Spiegelman, B.M. (2003) Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev., 24, 78-90.
36. Puigserver, P., Wu, Z., Park, C.W., Graves, R., Wright, M. and Spiegelman, B.M. (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell, 92, 829-839.
37. Lin, J., Handschin, C. and Spiegelman, B.M. (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1, 361-370.
38. Kelly, D.P. and Scarpulla, R.C. (2004) Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev., 18, 357-368.
39. Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., Tanese, N. and Krainc, D. (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127, 59-69.
40. Weydt, P., Pineda, V.V., Torrence, A.E., Libby, R.T., Satterfield, T.F., Lazarowski, E.R., Gilbert, M.L., Morton, G.J., Bammler, T.K., Strand, A.D. et al. (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab., 4, 349-362.
41. Lin, J., Wu, H., Tarr, P.T., Zhang, C.Y., Wu, Z., Boss, O., Michael, L.F., Puigserver, P., Isotani, E., Olson, E.N. et al. (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature, 418, 797-801.
42. Gizatullina, Z.Z., Lindenberg, K.S., Harjes, P., Chen, Y., Kosinski, C.M., Landwehrmeyer, B.G., Ludolph, A.C., Striggow, F., Zierz, S. and Gellerich, F.N. (2006) Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice. Ann. Neurol., 59, 407-411.
43. Kosinski, C.M., Schlangen, C., Gellerich, F.N., Gizatullina, Z., Deschauer, M., Schiefer, J., Young, A.B., Landwehrmeyer, G.B., Toyka, K.V., Sellhaus, B. et al. (2007) Myopathy as a first symptom of Huntington's disease in a Marathon runner. Mov. Disord., 22, 1637-1640.
44. Mihm, M.J., Amann, D.M., Schanbacher, B.L., Altschuld, R.A., Bauer, J.A. and Hoyt, K.R. (2007) Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis., 25, 297-308.
45. Strand, A.D., Aragaki, A.K., Shaw, D., Bird, T., Holton, J., Turner, C., Tapscott, S.J., Tabrizi, S.J., Schapira, A.H., Kooperberg, C. et al. (2005) Gene expression in Huntington's disease skeletal muscle: A potential biomarker. Hum. Mol. Genet., 14, 1863-1876.
46. Turner, C., Cooper, J.M. and Schapira, A.H. (2007) Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov. Disord., 22, 1715-1721.
47. Gines, S., Seong, I.S., Fossale, E., Ivanova, E., Trettel, F., Gusella, J.F., Wheeler, V.C., Persichetti, F. and MacDonald, M.E. (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet., 12, 497-508.
48. Fitch, C.D., Jellinek, M. and Mueller, E.J. (1974) Experimental depletion of creatine and phosphocreatine from skeletal muscle. J. Biol. Chem., 249, 1060-1063.
49. Shoubridge, E.A., Challiss, R.A., Hayes, D.J. and Radda, G.K. (1985) Biochemical adaptation in the skeletal muscle of rats depleted of creatine with the substrate analogue beta-guanidinopropionic acid. Biochem. J., 232, 125-131.
50. O'Gorman, E., Beutner, G., Wallimann, T. and Brdiczka, D. (1996) Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. Biochim. Biophys. Acta, 1276 161-170.
51. Yaspelkis, B.B. 3rd, Castle, A.L., Farrar, R.P. and Ivy, J.L. (1998) Effect of chronic electrical stimulation and beta-GPA diet on GLUT4 protein concentration in rat skeletal muscle. Acta Physiol. Scand. 163, 251-259.
52. Zong, H., Ren, J.M., Young, L.H., Pypaert, M., Mu, J., Birnbaum, M.J. and Shulman, G.I. (2002) AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to cjronic energy deprivation. Proc. Natl Acad. Sci. USA, 99, 15983-15987.
53. Jager, S., Handschin, C., St-Pierre, J. and Spiegelman, B.M. (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. USA, 104 12017-12022.
54. Stein, S.C., Woods, A., Jones, N.A., Davison, M.D. and Carling, D. (2000) The regulation of AMP-activated protein kinase by phosphorylation. Biochem. J., 345 (Pt 3), 437-443.
55. Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E. et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet., 34, 267-273.
56. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S. et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA, 102, 15545-15550.
57. Arany, Z., Lebrasseur, N., Morris, C., Smith, E., Yang, W., Ma, Y., Chin, S. and Spiegelman, B.M. (2007) The transcriptional coactivator PGC-1beta drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab., 5, 35-46.
58. Mootha, V.K., Handschin, C., Arlow, D., Xie, X., St Pierre, J., Sihag, S., Yang, W., Altshuler, D., Puigserver, P., Patterson, N. et al. (2004) Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc. Natl Acad. Sci. USA, 101, 6570-6575.
59. St-Pierre, J., Lin, J., Krauss, S., Tarr, P.T., Yang, R., Newgard, C.B. and Spiegelman, B.M. (2003) Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J. Biol. Chem., 278 26597-26603.
60. Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R.C. et al. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell, 98, 115-124.
61. Huss, J.M. and Kelly, D.P. (2004) Nuclear receptor signaling and cardiac energetics. Circ. Res., 95, 568-578.
62. Larsson, N.G., Wang, J., Wilhelmsson, H., Oldfors, A., Rustin, P., Lewandoski, M., Barsh, G.S. and Clayton, D.A. (1998) Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat. Genet., 18, 231-236.
63. Browne, S.E. and Beal, M.F. (2006) Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal, 8, 2061-2073.
64. Hersch, S.M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L. et al. (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 66, 250-252.
65. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Jager, S., Handschin, C., Zheng, K., Lin, J., Yang, W. et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 127, 397-408.
66. Arany, Z., He, H., Lin, J., Hoyer, K., Handschin, C., Toka, O., Ahmad, F., Matsui, T., Chin, S., Wu, P.H. et al. (2005) Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab., 1, 259-271.
67. Handschin, C., Kobayashi, Y.M., Chin, S., Seale, P., Campbell, K.P. and Spiegelman, B.M. (2007) PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev., 21, 770-783.
68. Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z.P., Lecker, S.H., Goldberg, A.L. and Spiegelman, B.M. (2006) PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl Acad. Sci. USA, 103, 16260-16265.
69. Schilling, G., Savonenko, A.V., Klevytska, A., Morton, J.L., Tucker, S.M., Poirier, M., Gale, A., Chan, N., Gonzales, V., Slunt, H.H. et al. (2004) Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice. Hum. Mol. Genet., 13, 1599-1610.
70. Handschin, C., Chin, S., Li, P., Liu, F., Maratos-Flier, E., Lebrasseur, N.K., Yan, Z. and Spiegelman, B.M. (2007) Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1alpha muscle-specific knock-out animals. J. Biol. Chem., 282, 30014-30021.
71. Ciammola, A., Sassone, J., Alberti, L., Meola, G., Mancinelli, E., Russo, M.A., Squitieri, F. and Silani, V. (2006) Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ., 13, 2068-2078.
72. Behan, W.M., Cossar, D.W., Madden, H.A. and McKay, I.C. (2002) Validation of a simple, rapid, and economical technique for distinguishing type 1 and 2 fibres in fixed and frozen skeletal muscle. J. Clin. Pathol., 55, 375-380.
73. Manfredi, G., Yang, L., Gajewski, C.D. and Mattiazzi, M. (2002) Measurements of ATP in mammalian cells. Methods, 26, 317-326.
74. Matthews, R.T., Yang, L., Jenkins, B.G., Ferrante, R.J., Rosen, B.R., Kaddurah-Daouk, R. and Beal, M.F. (1998) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci., 18, 156-163.
75. Blau, H.M. and Webster, C. (1981) Isolation and characterization of human muscle cells. Proc. Natl Acad. Sci. USA, 78, 5623-5627.
76. Martinov, V.N., Sefland, I., Walaas, S.I., Lømo, T., Njå, A. and Hoover, F. (2002) Targeting functional subtypes of spinal motoneurons and skeletal muscle fibers in vivo by intramuscular injection of adenoviral and adeno-associated viral vectors. Anat. Embryol., 205, 215-221.